Syntax Bio
- Biotech or pharma, therapeutic R&D
Syntax Bio's regenerative medicine discovery platform overcomes the longstanding challenges in stem cell derived therapies by directly controlling and accelerating iPSC differentiation. A shorter and more reliable iPSC differentiation process improves patient access by making stem cell discovery and manufacturing faster, less costly and scalable. Synatx’s proprietary Cellgorithm technology mimics human development using a sequential synthetic biology CRISPR based system to generate a wide diversity of functional cell types to enable new cell therapy and gene therapy product opportunities.
)
)
){kind=logo}
){kind=logo}
){kind=logo}